Business Context and Reporting Period
This Form 8-K Current Report was filed by Palisade Bio, Inc. on November 18, 2021. The filing primarily addresses corporate governance actions, including the adoption of a new inducement equity plan, specific executive equity grants, the repricing of legacy options, and the results of the 2021 Annual Meeting of Stockholders.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial data points provided relate to equity compensation and stockholder voting:
- Stock Price: $2.32 per share (closing price on November 18, 2021, used as the exercise price for new grants and repriced options).
- Shares Outstanding (Record Date): 12,929,911 shares as of October 1, 2021.
- Share Reserve: 750,000 shares reserved for the new 2021 Inducement Plan.
Material Changes and Corporate Actions
Equity Plan Adoptions and Grants
- 2021 Inducement Plan: Adopted without stockholder approval under Nasdaq Listing Rule 5635(c)(4) to attract new hires. 750,000 shares reserved.
- Executive Grants (2021 Equity Incentive Plan):
- CEO Thomas M. Hallam: 267,868 options at $2.32/share.
- CFO J.D. Finley: 178,091 options at $2.32/share.
- CMO Michael Dawson: 39,294 options at $2.32/share.
- Vesting: All grants vest quarterly (1/12th every three months).
- Option Repricing: Legacy options from the Leading Biosciences, Inc. 2013 Plan were repriced to $2.32/share. This affected:
- 243,194 options held by CEO Thomas M. Hallam.
- 161,687 options held by CFO J.D. Finley.
- 35,675 options held by CMO Michael Dawson.
2021 Annual Meeting Results
Approximately 63.5% of outstanding shares were present or represented by proxy. Key outcomes included:
- Director Election: Stephanie C. Diaz and Cristina Csimma were elected as Class I Directors.
- Auditor Ratification: BDO USA, LLP was ratified as the independent auditor.
- Equity Plan Amendment: Stockholders approved an amendment to the 2021 Equity Incentive Plan to correct a typographical error regarding the annual share reserve increase (corrected from 1% to 4% of outstanding shares).
- Executive Compensation: Advisory vote on executive compensation was approved.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or specific risk factors. The primary focus is on the execution of equity compensation strategies and the formalization of corporate governance through the Annual Meeting votes.
Investor Verification Checklist
- Verify the impact of the option repricing on existing dilution and the specific terms of the legacy Leading Biosciences options.
- Review the 2021 Equity Incentive Plan amendment (Exhibit 10.6) to confirm the corrected 4% annual share reserve increase mechanism.
- Monitor the utilization of the 750,000 share reserve in the new Inducement Plan for future hiring.
- Confirm the voting percentages for the executive compensation advisory vote, noting that approximately 23% of votes cast were against the proposal.